A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Phase 4
832
about 10 months
12+
5 sites in GA, LA, MS +1
What this study is about
This trial is testing a new type of COVID-19 vaccine called mNEXSPIKE® that contains a variant of the virus. The goal is to see how well it creates an immune response (immunogenicity) and whether it's safe for people, including adults and children.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive mRNA-1283.251 Variant-containing Formulation
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Subprotocol 1: Part A - Number of Participants with Unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interests (AESIs), and AEs Leading to Study Withdrawal, Subprotocol 1: Part B - Number of Participants with SAEs, AESIs, and AEs Leading to Study Withdrawal, Subprotocol 1: Part B - Number of Participants with Unsolicited AEs
Infectious